← Eichor
Study identifier: NCT06482853 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

Condition: Obesity · Hypertension  ·  Sponsor: Milton S. Hershey Medical Center

PhaseEARLY_Phase 1
Planned participants52
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.

This description comes directly from the study's public registry record.

Talk to the study team

Aimee Cauffman, RN  ·  717-531-1617  ·  acauffman@pennstatehealth.psu.edu

Amy Arnold, PhD  ·  717-531-3674  ·  aarnold5@pennstatehealth.psu.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Penn State Milton S. Hershey Medical CenterHershey, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06482853